A year of the experimental treatment fenebrutinib suppressed nearly all disease activity in people with relapsing MS in a ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Fenebrutinib is a small molecule commercialized by Roche, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS).

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

Roche to present positive phase II FENopta OLE study data of BTK inhibitor, fenebrutinib to treat relapsing MS at 40th Congress of ECTRIMS: Basel Thursday, September 5, 2024, 13:0 ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...

Roche has three ongoing Phase III trials of its BTK inhibitor fenebrutinib in patients with relapsing multiple sclerosis.

Communicating my experience with MS is important, columnist Ben Hofmeister says, but so is making sure the other person comprehends it.